Funder
ORNATE India research Grant GCRF UKRI
Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, et al. Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial. Ophthalmology. 2020;127:186–95.
2. Halawa OA, Lin JB, Miller JW, Vavvas DG. A review of completed and ongoing complement inhibitor trials for geographic atrophy secondary to age-related macular degeneration. J Clin Med. 2021;10:2580.
3. Holz FG, Sadda SR, Busbee B, Chew EY, Mitchell P, Tufail A, et al. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials. JAMA Ophthalmol. 2018;136:666–77.
4. ReCLAIM-2 Study to evaluate safety, efficacy & pharmacokinetics of elamipretide in subjects with AMD with non-central GA. 2022; Available from: https://ClinicalTrials.gov/show/NCT03891875.
5. FocuS: First in human study to evaluate the safety and efficacy of GT005 administered in subjects with Dry AMD. 2022 10 January 2022; Available from: https://ClinicalTrials.gov/show/NCT03846193.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献